Search results
Results from the WOW.Com Content Network
The MTBE controversy concerns methyl tert-butyl ether (MTBE), a gasoline additive that replaced tetraethyllead.MTBE is an oxygenate and raises gasoline's octane number.Its use declined in the United States in response to environmental and health concerns.
Methyl tert-butyl ether (MTBE), also known as tert-butyl methyl ether, is an organic compound with a structural formula (CH 3) 3 COCH 3. MTBE is a volatile, flammable, and colorless liquid that is sparingly soluble in water. [ 1 ]
Nevertheless, the World Health Organization discussed a possible link between BHT and cancer risk in 1986, [36] [page needed] [verification needed] [needs update] and some primary research studies in the 1970s–1990s reported both potential for increased risk and potential for decreased risk in the area of oncology.
Chronic exposure to TEL can cause long-term negative effects such as memory loss, delayed reflexes, neurological problems, insomnia, tremors, psychosis, loss of attention, and an overall decrease in IQ and cognitive function. [91] The carcinogenity of tetraethyllead is debatable. It is believed to harm the male reproductive system and cause ...
tert-Butyl alcohol is used as a solvent, ethanol denaturant, paint remover ingredient, and gasoline octane booster and oxygenate.It is a chemical intermediate used to produce methyl tert-butyl ether (MTBE) and ethyl tert-butyl ether (ETBE) by reaction with methanol and ethanol, respectively, and tert-butyl hydroperoxide (TBHP) by reaction with hydrogen peroxide.
An ether: Methyl tert-butyl ether; Methyl n-butyl ether (CH 3-O-C 4 H 9 This page was last edited on 4 July 2022, at 09:26 (UTC). Text is available under the ...
Isobutane is oxidized to tert-butyl hydroperoxide, which is subsequently reacted with propylene to yield propylene oxide. The tert-butanol that results as a by-product is typically used to make gasoline additives such as methyl tert-butyl ether (MTBE).
In the EPC trial, in which bicalutamide monotherapy (150 mg/day) was evaluated for treatment of early prostate cancer in 8,113 men, the incidence of abnormal liver function tests at 3-year median follow-up was 3.4% for bicalutamide plus standard care (n=4,052) and 1.9% for standard care alone (n=4,061).